Sustained-Release Medication Technology Reviewed

Posted on

Ophthalmologists and their patients with glaucoma would welcome an implant that delivers medication when needed. Jason Bacharach, MD, founding partner and medical director, North Bay Eye Associates in Sonoma County, CA, recently addressed this possibility. He said an implant that offers sustained-release medication can be viewed as “ancillary treatment” where medicine is still delivered via a MIGS-type device that is eventually replaced. Dr Bacharach likened the emerging technology to coated stents used in cardiology. 

He and his colleagues reviewed the devices that are getting closer to use in practice and examined the stumbling blocks that remain. 

You can read more here.

Lipner M, Farid M. Examining the sustained front. [Published online May 2018]. Eye World.


Related Articles
IOP outcomes after laser trabeculoplasty in eyes with prior Kahook Dual Blade goniotomy limited
Jul 28, 2021
Hydrus microstent reduces IOP, medication burden
Jul 26, 2021
IOP, gel microstents complications leading cause of reoperation after MIGS
Jul 23, 2021
Click to access the login or register cheese